Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038100 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,301
- Enrollment target
- 20
- Study locations
NCT03038100 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,301 participants, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03038100, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,301 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Paclitaxel
- DRUG Atezolizumab Placebo
Study Locations (20)
California
- Moores Cancer Center at UC San Diego Health - La Jolla
- LAC + USC Medical Center - Los Angeles
- UCLA - School of Medicine - Los Angeles
- Kaiser Permanente - Oakland - Oakland
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange - Orange
- UC Irvine Medical Center - Orange
- Stanford University - Palo Alto
- Kaiser Permanente - Sacramento - Roseville
- Southern California Kaiser Permanente - San Diego
- California Pacific Medical Center Research Institute - San Francisco
- K. Permanente - San Fransisco - San Francisco
- University of California San Francisco Cancer Center - San Francisco
- Kaiser Permanente - Santa Clara - Santa Clara
- Olive View/Ucla Medical Center - Sylmar
- Kaiser Permanente - Walnut Creek - Walnut Creek
Arizona
- St. Joseph'S Hospital & Medical Center - Phoenix
- Arizona Oncology Associates, PC - HAL - Scottsdale
- Arizona Oncology - HOPE Wilmot - Tucson
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
Connecticut
- Danbury Hospital - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,301 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2022-08-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038100
The ClinicalTrials.gov registry entry for NCT03038100 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,301 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03038100 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03038100 about?
NCT03038100 is a clinical study titled "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tub...
What is the current status of trial NCT03038100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,301 participants. The study started on 2017-03-08. Estimated completion is 2022-08-12.
What conditions does trial NCT03038100 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT03038100?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Atezolizumab (DRUG), Paclitaxel (DRUG), Atezolizumab Placebo (DRUG).
Who is sponsoring clinical trial NCT03038100?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03038100 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.